Intravenous zoledronate (Reclast) administered once every 5 years reduced the incidence of morphometric vertebral fractures in early postmenopausal women, a randomized trial showed. Over 10 years of ...

Following an infusion of zoledronate acid in low-risk postmenopausal women, fracture risk reduction emerged only 5-10 years later in a placebo-controlled trial. By year 10, those who received a single ...

Please provide your email address to receive an email when new articles are posted on . Discontinuation of denosumab is associated with a rapid return to pretreatment BMD levels and an increased risk ...

The researchers found that 6.3, 6.6, and 11.1% of the zoledronate-zoledronate, zoledronate-placebo, and placebo-placebo groups, respectively, had a new morphometric fracture at follow-up. HealthDay ...

Women in early menopause treated with zoledronate in just two infusions, 5 years apart, show a significantly reduced risk of sustaining a vertebral fracture and better maintenance of bone mineral ...

MESSINA, Italy — Although the bisphosphonate zoledronic acid, or zoledronate (Aclasta, Reclast, Novartis), stops bone loss in patients with osteoporosis, it also ups levels of the protein biomarker ...

Please provide your email address to receive an email when new articles are posted on . “The need to establish treatment efficacy in osteopenia has become more pressing, given the clinical trend to ...

With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you. Yes, I want to Gift Aid any donations made to NAM now, in the future and in the past four years I am a UK ...

Editor's note: This story was updated on Oct. 23, to add conflict-of-interest disclosures for the lead author of the research study. A large study has produced strong evidence that a drug commonly ...

Benefits of infrequent zoledronate acid (Reclast) infusions were seen later rather than sooner for low-risk women, a secondary analysis of a randomized trial indicated. Among 1,054 early ...